Jatenzo Cost in Washington: 2026 Prices, Insurance, and Savings Options

What Jatenzo Actually Costs at Washington Pharmacies in 2026

The manufacturer list price from Tolmar Pharmaceuticals sits at approximately $900 per month, and the average cash-pay price across Washington retail pharmacies tracks that figure closely [1]. That number reflects the wholesale acquisition cost (WAC) passed through without insurance negotiation. No FDA-approved generic of oral testosterone undecanoate exists as of May 2026, which keeps competitive pricing pressure low.

Retail Pharmacy Variation Across Washington

Prices at individual pharmacies in Seattle, Spokane, and Tacoma can fluctuate by $50 to $150 depending on whether the pharmacy participates in discount networks. Costco and certain independent pharmacies may offer slightly lower cash-pay rates. GoodRx-type discount cards sometimes reduce the price to the $700 to $850 range, but these coupons do not stack with insurance benefits or the Tolmar manufacturer card.

How $900 Compares to Injectable TRT

Injectable testosterone cypionate, the most common alternative, runs $30 to $80 per month at most Washington pharmacies for a standard 200 mg/mL vial [2]. The roughly 10-to-1 cost gap between oral and injectable testosterone is the primary barrier most patients encounter. The Endocrine Society's 2018 clinical practice guideline recognizes both formulations as appropriate for male hypogonadism but does not express a preference based on cost [3].

Washington Medicaid Coverage for Jatenzo

Washington Apple Health (Medicaid) covers Jatenzo with prior authorization (PA). The PA process requires documented evidence of male hypogonadism confirmed by two morning serum testosterone levels below 300 ng/dL, consistent with FDA labeling criteria [1][4].

Prior Authorization Steps

The prescribing clinician submits a PA request to the patient's managed care organization (MCO) or to the Health Care Authority fee-for-service program. Required documentation typically includes two morning total testosterone values (drawn before 10 a.m.), a clinical diagnosis of hypogonadism, and a rationale for selecting oral therapy over injectable alternatives. Turnaround is usually 48 to 72 hours. Washington's Medicaid drug formulary aligns with the FDA-approved indication: treatment of hypogonadism in adult males who have conditions associated with a deficiency or absence of endogenous testosterone [4].

What Happens if PA Is Denied

If the MCO denies coverage, Washington law provides a two-level appeal process. Patients can also request an independent review through the Office of the Insurance Commissioner. In practice, denials most frequently cite missing lab documentation or failure to trial a less expensive injectable first [5].

Insurance Coverage Beyond Medicaid

Commercial Plans in Washington

Most large commercial insurers operating in Washington, including Premera Blue Cross, Regence BlueCross BlueShield, and Kaiser Permanente of Washington, list Jatenzo on their formularies at a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) level. Tier 3 placement typically means a $50 to $100 copay; Tier 4 can push the copay to $100 to $200 per month before any manufacturer coupon is applied [6].

Step therapy requirements are common. Several Washington commercial plans require documentation that the patient either cannot tolerate injectable testosterone or has a clinical contraindication to it. The American Urological Association's 2018 guideline on testosterone deficiency supports oral testosterone undecanoate as a reasonable option for patients who prefer non-injectable routes [7].

Medicare Part D

Medicare Part D plans may cover Jatenzo, but coverage varies by plan. The donut hole (coverage gap) can expose patients to significant out-of-pocket costs. Patients in the catastrophic coverage phase pay roughly 5% of the drug cost. The Tolmar savings card is not valid for Medicare beneficiaries due to federal anti-kickback statutes [8].

How the Tolmar Savings Card Works in Washington

Tolmar offers a manufacturer savings card for commercially insured patients. Eligible patients with commercial insurance may pay as little as $0 per month out of pocket, with a maximum annual benefit cap (typically $6,000 to $9,000 per year, though terms update periodically) [1].

Eligibility Rules

The card is available to patients with commercial insurance only. It cannot be used with Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. Patients present the card at the pharmacy alongside their insurance card. The savings card covers the difference between the patient's copay and the program floor (often $0). Washington state does not restrict manufacturer copay assistance programs for commercially insured patients [9].

Activation and Renewal

Patients activate the card through the Tolmar website or by calling the program phone number printed on the card. Renewal is typically annual, and patients must re-enroll each calendar year. Some pharmacies in Washington can process the card electronically at point of sale without a physical card.

Compounded Oral Testosterone Undecanoate in Washington

Legal Status Under Washington Law

Compounded oral testosterone undecanoate is available in Washington through licensed 503A compounding pharmacies [10]. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound medications based on valid individual prescriptions. Washington's Pharmacy Quality Assurance Commission regulates these pharmacies under WAC 246-945.

Cost of Compounded Oral Testosterone Undecanoate

Compounded versions can cost substantially less than brand-name Jatenzo. Some 503A pharmacies in Washington offer compounded oral testosterone undecanoate for as little as $0 markup beyond the base compounding fee, particularly at pharmacies that compound in volume for men's health clinics. Realistic pricing ranges from $50 to $200 per month depending on the pharmacy, dose, and capsule count [10].

Clinical Considerations

Compounded products do not undergo the same FDA review process as branded drugs. The Swerdloff et al. Phase 3 trial (N=166) that supported Jatenzo's FDA approval demonstrated that oral testosterone undecanoate restored testosterone levels to the eugonadal range (300 to 1,100 ng/dL) in 87% of participants at the adjusted dose, with a specific self-emulsifying drug delivery system (SEDDS) that may differ from compounded formulations [11]. Clinicians should counsel patients that bioequivalence between compounded and branded formulations has not been established.

The FDA's 2020 advisory committee review noted a blood pressure increase of approximately 3 to 5 mmHg systolic with Jatenzo relative to placebo, a signal that led to the cardiovascular monitoring requirement on the label [4]. This finding applies to the branded formulation; no comparable controlled data exists for compounded oral testosterone undecanoate.

Getting Jatenzo via Telehealth in Washington

Washington permits telehealth prescribing of Jatenzo. The state adopted permanent telehealth parity legislation (SB 5385, effective 2021) requiring insurers to cover telehealth visits at the same rate as in-person visits [12]. A clinician licensed in Washington can prescribe Jatenzo after a telehealth evaluation that includes review of qualifying lab work.

Telehealth Prescribing Requirements

The prescriber must hold an active Washington medical license (or be authorized through an interstate compact). Labs confirming hypogonadism must be completed before the prescription is written. Several men's health telehealth platforms operating in Washington can order labs, evaluate results, and prescribe Jatenzo in a single workflow. The DEA does not classify testosterone undecanoate as requiring an in-person visit for initial prescribing under current federal telehealth rules, though testosterone is a Schedule III controlled substance [13][14].

Lab Monitoring on Jatenzo

The FDA label recommends checking hematocrit before starting therapy and at 3 months, 6 months, and annually thereafter [4]. The Endocrine Society guideline recommends monitoring serum testosterone, hematocrit, PSA, and lipid panels at 3 to 6 months after initiation and annually afterward [3]. Washington telehealth providers can order these labs at Quest, Labcorp, or local hospital draw stations.

Strategies to Lower Your Jatenzo Cost in Washington

Stack Insurance with the Tolmar Card

Patients with commercial insurance should apply the Tolmar savings card on top of their insurance benefit. This combination frequently reduces the monthly cost to $0 to $25 [1].

Ask About Therapeutic Alternatives

If cost is prohibitive and injectable therapy is acceptable, testosterone cypionate at $30 to $80 per month represents the lowest-cost FDA-approved option [2]. Testosterone enanthate is another injectable alternative with similar pricing. A 2020 meta-analysis of 19 randomized controlled trials (N=3,431) found no clinically meaningful difference in efficacy between injectable and oral testosterone formulations for achieving eugonadal testosterone levels [15].

Consider Compounded Formulations with Clinician Guidance

For patients who specifically want oral therapy but cannot afford Jatenzo, a compounded oral testosterone undecanoate from a Washington-licensed 503A pharmacy may cost $50 to $200 per month. Discuss this option with a clinician who can monitor therapeutic response via serum testosterone levels at 4 to 6 weeks after starting the compounded product [10][11].

Patient Assistance Programs

Tolmar's patient assistance program (PAP) may provide Jatenzo at no cost to uninsured patients who meet income eligibility criteria (typically at or below 300% of the federal poverty level). Application requires proof of income and a valid prescription [1].

Cardiovascular Monitoring and the Jatenzo Label

The FDA's 2019 approval of Jatenzo included a requirement for blood pressure monitoring due to dose-dependent increases in systolic blood pressure observed during clinical trials [4]. Swerdloff et al. Reported mean systolic BP increases of 3.3 mmHg in the treatment group at 12 months [11]. The 2024 update from the American Heart Association notes that testosterone therapy in hypogonadal men did not increase major adverse cardiovascular events (MACE) in the TRAVERSE trial (N=5,246), though that trial studied transdermal testosterone gel, not oral formulations [16][17].

Washington clinicians prescribing Jatenzo should measure blood pressure at baseline, at 1 month, and periodically thereafter per the FDA label. Patients with uncontrolled hypertension (systolic BP consistently above 140 mmHg) may not be appropriate candidates for oral testosterone undecanoate until blood pressure is managed [4][3].

Washington-Specific Pharmacy and Regulatory Notes

Washington's Pharmacy Quality Assurance Commission requires all pharmacies dispensing controlled substances (including testosterone products) to report to the state Prescription Drug Monitoring Program (PDMP). Prescribers must check the PDMP before writing a new testosterone prescription under WAC 246-919-985 [18]. This requirement applies to both Jatenzo and compounded testosterone products.

Washington does not impose a state-level quantity limit on Jatenzo prescriptions beyond what the FDA label recommends (a 30-day supply is standard). Some insurance plans may impose their own quantity limits as part of utilization management.